Medline (NASDAQ:MDLN) Upgraded at Rothschild Redb

Rothschild Redb upgraded shares of Medline (NASDAQ:MDLN) to a hold rating in a research report report published on Monday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. BNP Paribas started coverage on shares of Medline in a research note on Monday. They issued a “neutral” rating and a $38.00 price objective for the company. Rothschild & Co Redburn assumed coverage on Medline in a report on Monday. They issued a “neutral” rating and a $42.00 price target on the stock. BTIG Research assumed coverage on Medline in a research note on Monday. They set a “buy” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on Medline in a research report on Monday. They set an “overweight” rating and a $50.00 price objective on the stock. Finally, Royal Bank Of Canada initiated coverage on Medline in a research note on Monday. They issued an “outperform” rating and a $47.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $46.70.

Medline Price Performance

NASDAQ MDLN opened at $43.41 on Monday. Medline has a one year low of $34.89 and a one year high of $45.50.

Insider Buying and Selling

In other Medline news, Director Charles N. Mills purchased 2,579,310 shares of the stock in a transaction on Thursday, December 18th. The stock was acquired at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the acquisition, the director owned 2,441,379 shares in the company, valued at $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $28.37, for a total transaction of $172,727,085.27. Following the transaction, the insider owned 4,806,160 shares in the company, valued at approximately $136,350,759.20. This trade represents a 55.88% decrease in their position. The SEC filing for this sale provides additional information.

More Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.